Masthead

nCounter®
Breast Cancer 360™ Panel

Masthead

Helping Your Research

Want a system that provides a unique 360° view of gene expression for the breast tumor, microenvironment, and immune response? If yes, then you have found the right product. The Human nCounter Breast Cancer 360 panel and data analysis report helps researchers quickly decode the complexities of breast cancer biology, develop novel breast cancer gene signatures, and categorize disease heterogeneity using 48 biological signatures including signatures based upon the validated PAM50 and Tumor Inflammation Signature (TIS) assays. Get the most out of your panel by quickly distilling a large amount of data into actionable signatures measuring variables crucial to breast tumor-immune interaction.

Inspired by systems biology approaches to cancer research, NanoString’s 360 Series Panel Collection gives you a 360° view of gene expression by combining carefully-curated content involved in the biology of the tumor, microenvironment, and the immune response into a single holistic assay. Each panel contains the 18-gene Tumor Inflammation Signature (TIS) that measures a peripherally-suppressed, adaptive immune response and has been shown to correlate with response to checkpoint inhibitors.

Panel breakdown illustration

How It Works

The content included in the Breast Cancer 360 panel allows for a more comprehensive measurement of biological variables crucial to tumor progression and response to a wide range of treatments. Research signatures are enriched with potentially predictive genes involved in proliferation, endothelial, angiogenesis, cytotoxicity, stroma, inflammatory chemokines, and apoptosis.
01:

Highly Curated Content:

Expertly curated, comprehensive content includes 776 genes across 23 key breast cancer pathways and processes, 10 research focused signatures and 30 novel signatures measuring important tumor and immune activities.

02:

Comprehensive Coverage:

Expanded evaluation of breast cancer subtypes including: PAM50 Signature, TNBC, and Claudin-Low Signature.

03:

Interactive, Flexible Report:

The Interactive Breast Cancer 360 data analysis report provides insight into 48 signatures across 13 categories measuring biological variables crucial to breast cancer tumor biology.

You can access validated signatures like PAM50, Tumor Inflammation Signature (TIS), Risk of Recurrence (ROR)/Genomic Risk. Analyze your data by survival, response or grouping variables, or drill down into individual sample variability. Analyze clinical variables by TNBC/PAM50 subtype or variables of your choosing.

04:

Publication Ready Data:

The report generates figures, statistical outputs, methods for your publication, or poster presentation.

Panel Selection Tool

Find the gene expression panel for your research with easy to use panel pro

Find Your Panel

Product Information

Breast Cancer 360 Biological Signatures
Breast Cancer 360 Pathways and Processes
PAM50 and TIS Signatures
Product Specifications
Product Comparison
Breast Cancer 360 Biological Signatures
Breast Cancer 360 Pathways and Processes

Includes expertly curated 776 genes across 23 categories of breast cancer tumor biology to support the evaluation of pathways and process, as well as novel signature development.

PAM50 and TIS Signatures

Content included in the Breast Cancer 360 panel allows for a more comprehensive measurement of biological variables crucial to tumor progression and response to a wide-range of treatments. Research signatures are enriched with potentially predictive genes involved in proliferation, endothelial, angiogenesis, cytotoxicity, stroma, inflammatory chemokines, and apoptosis.

  • 48 signatures including two analytically validated signatures- PAM501,2 and Tumor Inflammation Signature3
  • 10 research-focused signatures and 30 novel signatures measuring important tumor and immune activities
  • adapted to decode breast cancer biology in concert

Analytically Validated Signatures

PAM50 Signature1,2

Included with the Breast Cancer 360 panel is the PAM50 Signature.  This 50-gene signature measures a gene expression profile that allows for the classification of breast cancer into four biologically distinct subtypes and a prognostic score.

  • PAM50 Subtype
    • Luminal A
    • Luminal B
    • HER2-Enriched
    • Basal-like
  • Prosigna Score / Risk of Recurrence

Tumor Inflammation Signature3

Included with the Breast Cancer 360 panel is the Tumor Inflammation Signature. This 18-gene signature measures activity known to be associated with response to PD-1/PD-L1 inhibitors pathway blockade3.

  • Includes 4 areas of immune biology used to determine peripherally suppressed immune response and the identification of “hot” or “cold” tumors
    • Antigen Presenting Cells
    • T Cell/NK presence
    • IFNγ Biology
    • T Cell Exhaustion
  • Tissue-of-origin agnostic (Pan-cancer)
  • Potential surrogate for PD-L1 and mutational load in research setting4

View publication and video.

Product Specifications
Product Comparison

360 Series Product Comparison

Fully-annotated gene lists in Excel format are available for each of the 360 Panels. The table below compares the biology coverage of the 360 Panels across the tumor, microenvironment, and the immune response to that of the PanCancer Panels Collection.

Related Resources

See All Resources
Product Bulletin Breast Cancer 360 – Product Bulletin
Report BC 360 Data Analysis Report – Flyer
Report BC360 Demo Data Analysis Report
Report BC360 Time Series Demo Data Analysis Report
Report BC360 TNBC Demo Data Analysis Report

Spatial proteomic characterization of HER2-positive breast tumors through neoadjuvant therapy predicts response.

The addition of HER2-targeted agents to neoadjuvant chemotherapy has dramatically improved pathological complete response (pCR) rates in early-stage, HER2-positive breast cancer. Nonetheless, up to 50% of patients have residual disease after treatment, while others are likely overtreated.

Molecular risk markers related to local tumor recurrence at histological margin-free endoscopically resected early gastric cancers: A pilot study.

Local recurrences in early gastric cancers (EGCs) after complete endoscopic submucosal dissection (ESD) remain problematic. Here, we investigated the spatially sequential molecular changes in various cancer-related proteins along the axis of the histologically clear but recurrent resection margins (TRM) to determine the appropriate tumor-free margin distance and potential molecular risk markers related to local recurrence.

PAM50 Intrinsic Subtype Profiles in Primary and Metastatic Breast Cancer Show a Significant Shift toward More Aggressive Subtypes with Prognostic Implications.

Background: PAM50 breast cancer intrinsic subtyping adds prognostic information in early breast cancer; however, the role in metastatic disease is unclear. We aimed to identify PAM50 subtypes in primary tumors (PTs) and metastases to outline subtype changes and their prognostic role.

Skysphere

Contact Us

Have questions or simply want to learn more?

Contact our helpful experts and we’ll be in touch soon.

Contact Us